<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912040</url>
  </required_header>
  <id_info>
    <org_study_id>123Iodine MIBG</org_study_id>
    <nct_id>NCT01912040</nct_id>
  </id_info>
  <brief_title>Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use</brief_title>
  <official_title>A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice
      to help in patient management decisions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be assessing for adverse reactions of patients injected with locally manufactured 123
      Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any
      potential immediate side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of the 123Iodine MIBG</measure>
    <time_frame>BP and Heart rate for 24 hours after injection.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Adrenergic Pathology</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Administration of 123Iodine MIBG to the patients referred .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of 123Iodine MIBG</intervention_name>
    <description>Patients will be administered the locally produced 123 Iodine MIBG</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>None applicable</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Those patients referred for MIBG assessment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with potential Adrenergic pathology

        Exclusion Criteria:

          -  Pregnant or breast feeding females

          -  Hypersensitivity to MIBG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division Head, Nuclear Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Ross, MD</last_name>
    <phone>902-473-7770</phone>
    <email>aross@dal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Kelly, B.T.</last_name>
    <phone>902-473-4377</phone>
    <email>chrisitna.kelly@cdha.nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Andrew Ross</investigator_full_name>
    <investigator_title>Division Head, Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Safety profile</keyword>
  <keyword>locally produced 123 Iodine MIBG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

